Egnyte Releases Life Science Data Management Trends Report
Egnyte commissioned GatePoint Research to query 152 executives in Regulatory Affairs, R&D, Clinical and Quality about the challenges facing data-driven, mission-critical companies as they try to maintain GxP compliance, specifically around data integrity and data privacy and security.
The report looks at how the biotechs efficiently and securely manage collaboration and data and unveils some interesting results. One of the findings is that the most popular applications used to manage regulated data are not designed for life sciences specifically. In such a specialized field, this can lead to trouble.
Another finding the report points to is a divide developing amongst life scenes organizations. There are technology adopters and there are organizations that still operate from manual processes leading to friction in collaborating with partners and difficulty maintaining compliance with regulations.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
